Sort   by:  
 Page size 
GenomicsGeobacillus sp. PLS 41
Geobacillus sp. PLS 41 Genome sequencing
PRJNA1354654 | ENA
GenomicsGeobacillus sp. PLS 41
Geobacillus sp. PLS 41 Genome sequencing
PRJNA1078113 | ENA
GenomicsProteus mirabilis strain:PLS
Proteus mirabilis strain:PLS Genome sequencing
PRJNA1480257 | ENA
TranscriptomicsGene expression profile analysis of PLS-123 in OCI-Ly7 cells
To exploit targets or signaling pathways affected by PLS-123 during anti-tumor process, gene expression profiling was carried out in representative OCI-Ly7 cells treated for 48 hours. OCI-Ly7 cells were treated with ibrutinib, PLS-123 or vehicle for 48 hours.
ORGANISM(S): Homo sapiens 
2015-02-11 | E-GEOD-65816 | biostudies-arrayexpress
TranscriptomicsGene expression profile analysis of PLS-123 in xenograft model.
To exploit targets or signaling pathways affected by PLS-123 during anti-tumor process, gene expression profiling was carried out in OCI-Ly7 inoculated xenograft model. Six- to eight-week-old male SCID mice were inoculated subcutaneously with OCI-Ly7 tumor cells in 0.1 ml PBS for tumor development
ORGANISM(S): Homo sapiens 
2015-02-11 | E-GEOD-65817 | biostudies-arrayexpress
ModelsVenkatraman2011 - PLS-UPA behaviour in the presence of substrate competition_1_1_1_1
Venkatraman2011 - PLS-UPA behaviour in the presence of substrate competition The posibility of ultrasensitivity and bistable activation of PLS (Plasmin) and UPA (Urokinase-type plasminogen activator) in the presence of substrate competition is explained here using a mathematical model.  ...
2024-09-02 | BIOMD0000000630 | BioModels
ModelsVenkatraman2012 - Interplay between PLS and TSP1 in TGF-β1 activation
Venkatraman2012 - Interplay between PLS and TSP1 in TGF-β1 activation The interplay between PLS (Plasmin) and TSP1 (Thrombospondin-1) in TGF-β1 (Transforming growth factor-β1)is shown using mathematical modelling and in vitro experimentents. ...
2024-09-02 | BIOMD0000000447 | BioModels
GenomicsPrognostic Liver Signature for NAFLD (PLS-NAFLD) profiles of cell-based PLS system treated with free fatty acids (FFA) and IDO1 inhibitor, epacadostat.
Prognostic Liver Signature for NAFLD (PLS-NAFLD) profiles of cell-based PLS system treated with free fatty acids (FFA) and IDO1 inhibitor, epacadostat.
PRJNA824585 | ENA
OtherPrognostic Liver Signature for NAFLD (PLS-NAFLD) profiles of cell-based PLS system treated with free fatty acids (FFA) and IDO1 inhibitor, epacadostat.
Non-alcoholic fatty liver disease (NAFLD), alongside the global obesity epidemic, is rapidly emerging as a dominant liver disease etiology that leads to progressive liver fibrosis, its terminal stage, cirrhosis, and hepatocellular carcinoma (HCC). We identified and validated a 133-gene signature (Pr...
ORGANISM(S): Homo sapiens 
2022-07-01 | GSE200460 | GEO
TranscriptomicsGene expression profile analysis of PLS-123 in xenograft model.
To exploit targets or signaling pathways affected by PLS-123 during anti-tumor process, gene expression profiling was carried out in OCI-Ly7 inoculated xenograft model.
ORGANISM(S): Homo sapiens 
2015-02-11 | GSE65817 | GEO
Sort   by:  
 Page size